Doyle Z

Independent Practice, Ontario, Canada. Electronic address: zoe.doyle@uhn.ca.

8 papers · ORCID

ArticlePsilocybin

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression.

Kaczmarek ES, Rodrigues NB, Chisamore N +8

Europe PMC2026
ArticlePsilocybin

Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy.

Doyle Z, Chisamore N, Kaczmarek ES +9

Europe PMC2026
ArticlePsilocybin

Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial.

Johnson DE, Meshkat S, Kaczmarek ES +11

Europe PMC2025
ArticlePsilocybin

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression.

Brudner RM, Kaczmarek E, Blainey MG +9

Europe PMC2025
ArticlePsilocybin

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude.

Chisamore N, Kaczmarek ES, Doyle Z +8

Europe PMC2025
ArticlePsilocybin

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder.

Meshkat S, Kaczmarek E, Doyle Z +7

Europe PMC2025
ArticlePsilocybin

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.

Chisamore N, Johnson D, Chen MJQ +6

Europe PMC2024
ArticleKetamine

A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study).

Rosenblat JD, deVries FE, Doyle Z +9

Europe PMC2023